Celerion has added a bronchoscopy suite in the Belfast, Northern Ireland, UK facility, to expand its respiratory capabilities.
The company can perform bronchoalveolar lavage (BAL) using study participants from its database.
The bronchoscopy suite enables Celerion to discover the expression and quantification of protein biomarkers within the fluid lining of the lower respiratory tract.
Celerion clinical research vice president Phil Bach said the company has conducted a number of studies that include mild to moderate and severe asthmatics, COPD and Cystic Fibrosis patients.
"Due to an increasing demand from clients for analysis of BAL samples, the dedicated Bronchoscopy Suite offers on-site access to this procedure," Bach added.
"This investment continues to demonstrate Celerion's response to the market's increasing demand for conducting Phase I studies in patients with access to more specialized techniques."
